Deltex Medical Group PLC Notice of results, AGM and investor presentation (3264V)
April 13 2021 - 6:30AM
UK Regulatory
TIDMDEMG
RNS Number : 3264V
Deltex Medical Group PLC
13 April 2021
Tuesday 13 April 2021
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Announcement of year end results, AGM and investor
presentation
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring, announces today that it intends to
publish its results for the year ended 31 December 2020 on Thursday
22 April 2021.
It also intends to hold the Annual General Meeting at 11.00 am
on Thursday 27 May 2021 at its premises at Terminus Road,
Chichester PO19 8TX. In line with government advice, Deltex Medical
discourages shareholders from attending the AGM in person, but at
the same time would strongly encourage shareholders to vote by
proxy.
Following the AGM Andy Mears, CEO, will provide a live
presentation related to a Company Update via the Investor Meets
Company platform on 27(th) May 2021 at 12:00pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Deltex Medical Group PLC (DEMG) via:
https://www.investormeetcompany.com/deltex-medical-group-plc/register-investor
Investors who already follow DEMG on the Investor Meet Company
platform will automatically be invited.
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@deltexmedical.com
Andy Mears, Chief Executive
David Moorhouse, Group Finance
Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Ben Cryer info@arden-partners.com
Paul Shackleton
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI)
Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
Zoe Alexander
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary oesophageal Doppler
monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity
in the central circulation in real time. Minimally invasive, easy
to set-up and quick to focus, the technology generates a
low-frequency ultrasound signal which is highly sensitive to
changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base
demonstrating both the clinical and economic benefits of its core
technology, TrueVue Doppler. This technology has been proven in a
wide range of clinical trials to reduce complications suffered by
patients after surgery and consequently save hospitals the costs of
treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocol for surgical patients.
Consequently, the Group's focus is on maximising value from the
opportunities presented, as enhanced haemodynamic management is
adopted into routine clinical practice around the world. The Group
aims to provide clinicians with a single platform - a 'haemodynamic
workstation' - which offers them a range of technologies from
simple to sophisticated to be deployed according to the patient's
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBBGDSCGBDGBX
(END) Dow Jones Newswires
April 13, 2021 07:30 ET (11:30 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024